Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q

Chromosome 1 is involved in quantitative anomalies in 50–60% of breast tumours. However, the structure of these anomalies and the identity of the affected genes remain to be determined. To characterise these anomalies and define their consequences on gene expression, we undertook a study combining array-CGH analysis and expression profiling using specialised arrays. Array-CGH data showed that 1p was predominantly involved in losses and 1q almost exclusively in gains. Noticeably, high magnitude amplification was infrequent. In an attempt to fine map regions of copy number changes, we defined 19 shortest regions of overlap (SROs) for gains (one at 1p and 18 at 1q) and of 20 SROs for losses (all at 1p). These SROs, whose sizes ranged from 170 kb to 3.2 Mb, represented the smallest genomic intervals possible based on the resolution of our array. The elevated incidence of gains at 1q, added to the well-established concordance between DNA copy increase and augmented RNA expression, made us focus on gene expression changes at this chromosomal arm. To identify candidate oncogenes, we studied the RNA expression profiles of 307 genes located at 1q using a home-made built cDNA array. We identified 30 candidate genes showing significant overexpression correlated to copy number increase. In order to substantiate their involvement, RNA expression levels of these candidate genes were measured by quantitative (Q)-RT–PCR in a panel of 25 breast cancer cell lines previously typed by array-CGH. Q–PCR showed that 11 genes were significantly overexpressed in the presence of a genomic gain in these cell lines, and 20 overexpressed when compared to normal breast.

[1]  S. Gendler,et al.  MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation , 2004, Oncogene.

[2]  J Isola,et al.  Molecular cytogenetics of primary breast cancer by CGH , 1998, Genes, chromosomes & cancer.

[3]  H. Höfler,et al.  Increasing chromosome 1 copy number parallels histological progression in breast carcinogenesis , 2000, British Journal of Cancer.

[4]  N. Agnantis,et al.  Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression. , 1999, Journal of experimental & clinical cancer research : CR.

[5]  Nicolas Stransky,et al.  Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas. , 2005, Cancer research.

[6]  I. Wistuba,et al.  Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. , 2000, Cancer genetics and cytogenetics.

[7]  R. Redon,et al.  Genomic and Expression Profiling of Chromosome 17 in Breast Cancer Reveals Complex Patterns of Alterations and Novel Candidate Genes , 2004, Cancer Research.

[8]  Barbara J. Trask,et al.  Array Comparative Genomic Hybridization Analysis of Genomic Alterations in Breast Cancer Subtypes , 2004, Cancer Research.

[9]  G. Mills,et al.  Emerging role of RAB GTPases in cancer and human disease. , 2005, Cancer research.

[10]  J. Radich,et al.  Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. , 2004, Blood.

[11]  P. Cornillet‐Lefèbvre,et al.  Compilation of published comparative genomic hybridization studies. , 2002, Cancer genetics and cytogenetics.

[12]  D. Birnbaum,et al.  Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. , 1997, Cancer research.

[13]  M. Teixeira,et al.  Cytogenetic clues to breast carcinogenesis , 2002, Genes, chromosomes & cancer.

[14]  C. Poremba,et al.  Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways , 1999, The Journal of pathology.

[15]  J. Andersen,et al.  Karyotypic evolution in breast carcinomas with i(1)(q10) and der(1;16)(q10;p10) as the primary chromosome abnormality. , 1999, Cancer genetics and cytogenetics.

[16]  I. Bièche,et al.  MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid. , 1997, Thyroid : official journal of the American Thyroid Association.

[17]  E. Ariazi,et al.  Estrogen-related Receptor α and Estrogen-related Receptor γ Associate with Unfavorable and Favorable Biomarkers, Respectively, in Human Breast Cancer , 2002 .

[18]  G. Mills,et al.  The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers , 2004, Nature Medicine.

[19]  R. Osborne,et al.  A genome-wide map showing common regions of loss of heterozygosity/allelic imbalance in breast cancer. , 2000, Cancer research.

[20]  Roland Eils,et al.  High-Resolution Genomic Profiling Reveals Association of Chromosomal Aberrations on 1q and 16p with Histologic and Genetic Subgroups of Invasive Breast Cancer , 2006, Clinical Cancer Research.

[21]  F. Bertucci,et al.  Comprehensive Profiling of 8p11-12 Amplification in Breast Cancer , 2005, Molecular Cancer Research.

[22]  F. Bertucci,et al.  Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.

[23]  E. Korn,et al.  Chromosome Transfer Induced Aneuploidy Results in Complex Dysregulation of the Cellular Transcriptome in Immortalized and Cancer Cells , 2004, Cancer Research.

[24]  Jorma Isola,et al.  Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. , 2003, Cancer research.

[25]  J. Inazawa,et al.  Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. , 2004, The American journal of pathology.

[26]  S. Meier-Ewert,et al.  A Novel Gene (PLU-1) Containing Highly Conserved Putative DNA/Chromatin Binding Motifs Is Specifically Up-regulated in Breast Cancer* , 1999, The Journal of Biological Chemistry.

[27]  Timothy W Corson,et al.  KIF14 is a candidate oncogene in the 1q minimal region of genomic gain in multiple cancers , 2005, Oncogene.

[28]  R Berger,et al.  MLL-AF1q fusion resulting from t(1;11) in acute leukemia , 1999, Leukemia.

[29]  M. Ringnér,et al.  Impact of DNA amplification on gene expression patterns in breast cancer. , 2002, Cancer research.

[30]  E. Ariazi,et al.  Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. , 2002, Cancer research.

[31]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[32]  Daniel Birnbaum,et al.  Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications , 2003, BMC Cancer.

[33]  C. Theillet,et al.  Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. , 1997, Cancer research.